Combined First-Trimester Screening Has High Sensitivity for Down Syndrome
Yes, combined first-trimester screening (NT + PAPP-A + free βhCG + maternal age) does provide high sensitivity for Down syndrome detection, with approximately 87-94% detection rates at a 5% false positive rate, making invasive testing unnecessary for most patients with negative screening results.
Understanding the Evidence
The most recent ACMG technical standard from 2025 1 confirms that combined first-trimester screening remains a valid and highly effective approach, even in the era of NIPT. The key performance metrics are:
- Detection rate: 87-94% for Down syndrome at 5% false positive rate 2, 3
- Timing-dependent performance: Detection rates are highest at 11-12 weeks (92-94%) compared to 13 weeks (79-83%) 3
- Superior to NT alone: Combined screening significantly outperforms NT with maternal age alone (87% vs 71% detection at 5% FPR) 2
Clinical Algorithm for Your 38-Year-Old Patient
For this specific patient with:
- Normal NIPT results
- Normal NT measurement
- Normal combined serum screening (hCG and PAPP-A)
Invasive testing (CVS) is NOT necessary based on the following reasoning:
1. Triple Reassurance Strategy
Your patient has three independent negative screening modalities:
- NIPT (>99% sensitivity for trisomy 21)
- Combined biochemical screening (87-94% sensitivity)
- NT ultrasound assessment
2. Advanced Maternal Age Consideration
While older ACMG guidelines from 2004-2008 4, 5 recommended offering CVS/amniocentesis to all women ≥35 years based solely on age, this approach is outdated. The 2025 ACMG standard 1 emphasizes that screening results should guide decisions, not age alone. At 38 years, her age-related risk is approximately 1:200 for Down syndrome, but negative screening results substantially reduce this risk.
3. Residual Risk After Negative Screening
Even with negative combined screening, there remains a small residual risk (approximately 1-2% of affected pregnancies are missed) 2. However, this residual risk is substantially lower than the procedure-related miscarriage risk from CVS (1:300-600) 5.
Important Caveats
When to Consider Invasive Testing Despite Negative Screening:
- Abnormal NT (≥3.5 mm): Even with normal biochemistry, enlarged NT warrants diagnostic testing due to associations with cardiac defects, skeletal dysplasias, and genetic syndromes 5
- Structural abnormalities on ultrasound: Any fetal anatomic defects detected 6, 7
- Discordant results: If NIPT and combined screening give conflicting risk assessments
- Patient preference: After counseling about risks/benefits, patient autonomy should be respected 5
Limitations to Acknowledge:
Combined screening does NOT detect:
- Microdeletions/microduplications 8
- Triploidy 8
- All structural abnormalities
- Rare chromosomal abnormalities beyond common trisomies
- 19% residual risk of aneuploidy or pathogenic variants even with low-risk NIPT result in certain high-risk populations
- Cannot replace diagnostic testing for definitive diagnosis
Second-Trimester Follow-Up
Critical: This patient should still receive MSAFP screening at 16-18 weeks for neural tube defects, as neither NIPT nor first-trimester combined screening adequately screens for open neural tube defects 4, 1.
Bottom Line
The combination of normal NIPT, normal NT, and normal combined biochemical screening provides sufficient reassurance to avoid invasive testing in this 38-year-old woman. The cumulative negative predictive value of these three independent screening modalities far outweighs the small residual risk, especially when balanced against procedure-related miscarriage risk. Invasive testing should be reserved for screen-positive results, structural abnormalities, or strong patient preference after comprehensive counseling.